All In Biotech

Drug Trial Radar · NCT04305769

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: a Randomized, Double-blind, Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Jun 1, 2021

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
University of VirginiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Carilion Clinic; University of Southampton
First posted
Mar 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 105 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident cases of uncomplicated C. difficile infection (CDI) in hospitalized, or outpatient, persons aged 18 or older. The investigators hypothesis is that alanyl-glutamine supplementation will decrease recurrence and mortality from CDI and these outcomes will be associated with improvement of inflammatory markers and restoration of intestinal microbiota function.

Conditions

  • Clostridioides Difficile Infection
  • Clostridium Difficile Infection
  • Clostridium Difficile Diarrhea
  • Clostridia Difficile Colitis

Interventions

  • Alanyl-glutamineDrug

    The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with recurrent CDI.Time frame: Within 60 days post-treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • UVA Health Systems

    Charlottesville, Virginia · Recruiting

  • Carilion Clinic

    Roanoke, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.